Oneness Biotech Co., Ltd.

Oneness Biotech Co., Ltd. is a healthcare company specializing in the research, development, and sale of biotechnology-based pharmaceuticals and health products. Its primary function lies in the innovation and commercialization of new drugs, with a notable focus on treatments for diabetic foot ulcers, oncology therapies, and immune-related conditions. Key products and pipelines include Fespixon cream for diabetic foot ulcers, the advanced-stage ON101 for chronic wounds, anti-cancer candidates such as OB318, and other biologics targeting allergic and metabolic diseases. Beyond pharmaceuticals, Oneness Biotech is also involved in agricultural product cultivation, reflecting a diversified approach that incorporates both life sciences and organic agriculture. Operating primarily within Taiwan, the company supports healthcare innovation by advancing new therapeutics through clinical development stages. Oneness Biotech serves as a significant player within the health technology and pharmaceuticals sector, contributing to both domestic drug initiatives and broader biotechnology advancements in the market.